Chromatographic and immunochemical approaches to the analysis of the HIV protease inhibitor saquinavir in plasma

被引:15
|
作者
Wiltshire, HR
Wiltshire, BG
Clarke, AF
Worth, E
Prior, KJ
Tjia, JF
机构
[1] Roche Discovery Welwyn, Welwyn Garden City AL7 3AY, Herts, England
[2] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England
关键词
bioanalysis; HPLC/UV; radioimmunoassay; HIV protease inhibitor; saquinavir;
D O I
10.1006/abio.2000.4545
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The development of the HIV protease inhibitor saquinavir (Ro 31-8959) required a range of analytical methods for its measurement in biological fluids. This paper describes the development of isocratic, reverse-phase HPLC/UV methods for the routine measurement of plasma levels of the drug together with a more sensitive radioimmunoassay, The performance of the two assays is compared with that of an HPLC/MS/MS method previously published and has been shown to be satisfactory, with coefficients of variation of calibration standards and quality control samples within the usual outside limits of +/-15%. The HPLC/UV method can be routinely applied for concentrations down to 10-20 ng/ml and a lower limit of quantification of 1 ng/ml from 1 mi of human plasma is possible. The radioimmunoassay was developed for the specific measurement of saquinavir concentrations in human, HIV-positive plasma samples and has a lower limit of quantification of 0.5-1.0 ng/ml, Some preliminary findings suggested that it might not be specific in rat plasma and no attempts have been made to quantify any nonclinical samples with this technique. If still greater sensitivity is required, recourse can be made to the HPLC/MS/MS assay. (C) 2000 Academic Press.
引用
收藏
页码:105 / 114
页数:10
相关论文
共 50 条
  • [41] Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
    Harrigan, PR
    Hertogs, K
    Verbiest, W
    Pauwels, R
    Larder, B
    Kemp, S
    Bloor, S
    Yip, B
    Hogg, R
    Alexander, C
    Montaner, JSG
    AIDS, 1999, 13 (14) : 1863 - 1871
  • [42] Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir
    R.M.W. Hoetelmans
    C.H.W. Koks
    J.H. Beijnen
    P.L. Meenhorst
    J.W. Mulder
    D.M. Burger
    Pharmacy World and Science, 1997, 19 : 159 - 175
  • [43] Cytotoxic and Radiosensitizing effects of Saquinavir a Human Immunodeficiency Virus (HIV)-1 Protease Inhibitor in Thyroid Carcinoma Cells.
    Kelly, T.
    Gehrke, E.
    Brink, I.
    Moser, E.
    Pajonk, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S65 - S65
  • [44] Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir
    Hoetelmans, RMW
    Meenhorst, PL
    Mulder, JW
    Burger, DM
    Koks, CHW
    Beijnen, JH
    PHARMACY WORLD & SCIENCE, 1997, 19 (04): : 159 - 175
  • [45] High-performance liquid chromatographic assay of a new HIV-1 protease inhibitor, LB71350, in the plasma of dogs
    Jeong, YN
    Seo, MK
    Choi, YJ
    Kim, IC
    Lee, YH
    JOURNAL OF CHROMATOGRAPHY B, 1997, 703 (1-2): : 284 - 288
  • [46] The Use of Pharmacoscintigraphy to Elucidate Food Effects Observed with a Novel Protease Inhibitor (Saquinavir)
    C. J. Kenyon
    F. Brown
    G. R. McClelland
    I. R. Wilding
    Pharmaceutical Research, 1998, 15 : 417 - 422
  • [47] Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification
    Jain, R
    Agarwal, S
    Majumdar, S
    Zhu, XD
    Pal, D
    Mitra, AK
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 303 (1-2) : 8 - 19
  • [48] Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir
    Lorenzi, P
    Yerly, S
    Abderrakim, K
    Fathi, M
    Rutschmann, OT
    vonOverbeck, J
    Leduc, D
    Perrin, L
    Hirschel, B
    Battegay, M
    Burgisser, P
    Doorly, R
    Egger, M
    Erb, P
    Fierz, W
    Flepp, M
    Francioli, P
    Grob, P
    Gruninger, U
    Ledergerber, B
    Luthy, R
    Malinverni, R
    Matter, L
    Opravil, M
    Paccaud, F
    Pichler, W
    Rickenbach, M
    Rutschmann, O
    Vernazza, P
    AIDS, 1997, 11 (12) : F95 - F99
  • [50] Stability analysis for HIV infection delay model with protease inhibitor
    Pitchaimani, M.
    Monica, C.
    Divya, M.
    BIOSYSTEMS, 2013, 114 (02) : 118 - 124